目的 探討復(fù)方苦參注射液聯(lián)合替雷利珠單抗對(duì)非小細(xì)胞肺癌（NSCLC）化療患者近期療效、肝功能及免疫功能的影響。方法 選取中國人民解放軍聯(lián)勤保障部隊(duì)第九二一醫(yī)院收治的NSCLC化療患者120例為觀察對(duì)象，于2021年2月—2023年10月進(jìn)行研究，按照治療方案的不同分為對(duì)照組和試驗(yàn)組，各60例。兩組患者均給予多西他賽聯(lián)合順鉑化療方案，對(duì)照組在此基礎(chǔ)上給予替雷利珠單抗治療，試驗(yàn)組在對(duì)照組基礎(chǔ)上給予復(fù)方苦參注射液治療，21 d為1個(gè)周期，共行6個(gè)周期治療。比對(duì)兩組近期療效、肺功能指標(biāo)、血清腫瘤標(biāo)志物、免疫功能及不良反應(yīng)發(fā)生情況。結(jié)果 試驗(yàn)組臨床總有效率高于對(duì)照組［80.00%（48/60） vs 50.00%（30/60）］（P＜0.05）；治療后試驗(yàn)組肺功能指標(biāo)[用力肺活量（FVC）、氣流量峰值（PEF）及1 s用力呼氣容積（FEV1）]高于治療前（P＜0.05）；治療后試驗(yàn)組腫瘤標(biāo)志物[糖類抗原125（CA125）、癌胚抗原（CEA）、鱗狀細(xì)胞癌抗原（SCC）及細(xì)胞角蛋白19的可溶性片段（CYFRA21-1）]水平低于治療前（P＜0.05）；治療后試驗(yàn)組CD3⁺、CD4⁺、CD4⁺/CD8⁺水平呈現(xiàn)升高趨勢，CD8⁺水平呈下降趨勢，與對(duì)照組比較均具有顯著差異（P＜0.05）；試驗(yàn)組骨髓抑制、嘔吐及肝功能異常的發(fā)生率均低于對(duì)照組，但僅有肝功能異常情況比較無統(tǒng)計(jì)學(xué)意義（P＞0.05）。結(jié)論 對(duì)NSCLC化療患者給予復(fù)方苦參注射液聯(lián)合替雷利珠單抗治療安全有效，改善肺功能指標(biāo)，穩(wěn)定血清腫瘤指標(biāo)，提升免疫功能，且安全性高。

Objective To explore the effects of Compound Kushen Injection combined with tirelizumab on the short-term efficacy, liver function, and immune function of patients with non-small cell lung cancer (NSCLC) treated with chemotherapy. Methods A total of 120 patients with NSCLC treated with chemotherapy admitted to the 921st Hospital of PLA were selected as the observation objects, the study was conducted from February 2021 to October 2023. According to the different treatment schemes, they were divided into the control group and the experimental group, with 60 cases in each group. Both groups of patients were given a combination chemotherapy regimen of docetaxel and cisplatin. The control group was treated with tirelizumab on this basis, while the study group was treated with Compound Kushen Injection combined with tirelizumab on this basis, 21 d for one cycle, six cycles of treatment. The recent efficacy, lung function indicators, serum tumor markers, immune function, and incidence of adverse reactions were compared between two groups. Results The total clinical effective rate of the study group was higher than that of the control group [80.00% (48/60) vs 50.00% (30/60)] (P < 0.05). After treatment, the lung function indicators [forced vital capacity (FVC), peak expiratory flow (PEF), and forced expiratory volume in one second (FEV1)] in the study group were higher than those in the control group (P < 0.05); After treatment, the levels of tumor markers [carbohydrate antigen 125 (CA125), squamous cell carcinoma (SCC), Carcinoembryonic Antigen (CEA), and cytokeratin 19 fragment CYFRA21-1)] in the study group were lower than those in the control group (P < 0.05); After treatment, the CD3⁺, CD4⁺, CD4⁺/CD8⁺ data in the study group showed an increasing trend, while the CD8⁺ data showed a decreasing trend, with significant differences compared to the control group (P < 0.05); The incidence of bone marrow suppression, vomiting, and liver dysfunction in the study group was lower than that in the control group, but only the incidence of liver function abnormalities was not statistically significant (P < 0.05). Conclusion In patients with NSCLC treated with chemotherapy, the treatment of Compound Kushen Injection combined with tiralizumab is safe and effective, improved lung function indicators, stabilized serum tumor indicators, and enhanced immune function.

R979.1

長沙市科技計(jì)劃項(xiàng)目（ kq1907150）